home / stock / atha / atha articles

ATHA Articles, Athira Pharma Inc.

Stock Information
Company Name: Athira Pharma Inc.
Stock Symbol: ATHA
Market: NASDAQ
Website: athira.com
Menu
ATHA ATHA Quote ATHA Short ATHA News ATHA Articles ATHA Message Board
Get ATHA Alerts

News, Short Squeeze, Breakout and More Instantly...
Athira Completes Dosing in Alzheimer's Study, Stock Up | Benzinga

Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its ...
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients | Benzinga

Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer's disease (AD); LIFT-AD topline...

Athira Pharma to Participate in Upcoming May Conferences | Benzinga

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on ...

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer | Benzinga

BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused o...
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting | Benzinga

BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on...

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference | Benzinga

Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neu...

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates | Benzinga

Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; t...
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying | Benzinga

The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern aro...

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-?-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease | Benzinga

BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on ...

Athira Pharma to Participate in Jefferies London Healthcare Conference | Benzinga

BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on...
Next 10